

Triterpene Saponins from the Leaves of *Ilex pernyi*

by **Guang-Bo Xie**^{a)}, **Jiao Zheng**^{a)}, **Peng-Fei Tu**^{*a)}, and **Guo-Qing Liu**^{b)}

^{a)} School of Pharmaceutical Sciences, Peking University Health Science Center, NO. 38 Xueyuan Road, Beijing 100083, P. R. China (phone/fax: +86-10-82802750; e-mail: pengfeitu@vip.163.com)

^{b)} School of Basic Medical Sciences, Peking University Health Science Center, NO. 38 Xueyuan Road, Beijing 100083, P. R. China


Eight new triterpene saponins, ilexpernosides C–J (**1–8**, resp.), and eight known triterpene saponins were isolated from the 70% EtOH extract of the leaves of *Ilex pernyi*. The structures of the new compounds were elucidated by spectroscopic data and chemical degradation.

Introduction. – *Ilex pernyi* FRANCH. (Aquifoliaceae), an evergreen shrub, is distributed mainly in the Yangtze River valley and south region of Qinling Mountains in the P. R. China [1]. Its leaves are used as folk medicine to treat tussis and febris in China [2]. Several compounds isolated from the genus *Ilex* have been reported to possess interesting bioactivities. Triterpenes from *I. kudincha* [3][4], *I. cornuta*, and *I. latifolia* [5] exhibit inhibitory activity on acyl CoA cholesteryl acyl transferase (ACAT). Adenosine, isolated from *I. cornuta*, enhances coronary blood flow [6]. Triterpene saponins from *I. oblonga* inhibit tobacco mosaic virus (TMV) [7].

As a part of the systematic chemical investigation on this genus [8][9], we recently investigated the saponin constituents of *I. pernyi* [10]. Herein, we report the structural elucidation of the eight new compounds, ilexpernosides C–J (**1–8**, resp.), isolated from the leaves of *I. pernyi*, together with eight known compounds **9–16**.

Results and Discussion. – Compound **1** was obtained as a colorless gum. The HR-ESI-MS showed an $[M + Na]^+$ ion at 673.3944, in accordance with a molecular formula of $C_{36}H_{58}O_{10}$. Positive results for both *Liebermann–Burchard* and *Molish* reactions indicated a triterpene saponin. The ^{13}C -NMR spectrum (*Tables 1* and *2*) of **1** revealed 36 C-atom signals, of which 6 were assigned to a hexosyl unit, and the remaining 30 to the aglycon.

The 1H -NMR spectrum (*Table 3*) indicated the presence of five Me *singlets* at $\delta(H)$ 0.88, 0.91, 1.04, 1.38, and 1.63, one Me *doublet* at $\delta(H)$ 1.06 ($J = 6.5$), one O-bearing CH H-atom at $\delta(H)$ 4.21 (*dd*, $J = 12.0, 4.5$, H–C(3)), one oxygenated CH_2 group at $\delta(H)$ 3.66 and 4.28 (*AB*, $J = 11.0$, $CH_2(23)$), and one olefinic H-atom at $\delta(H)$ 5.54 (*br. s*, H–C(12)) in the aglycon moiety. The ^{13}C -NMR spectrum for aglycon moiety of **1** exhibited the signals due to one CO group at $\delta(C)$ 180.5 (*s*), one oxygenated quaternary C-atom at $\delta(C)$ 72.4 (*s*), one oxygenated CH group at $\delta(C)$ 82.0 (*d*), one oxygenated CH_2 group at $\delta(C)$ 64.4 (*t*), and two olefinic C-atoms at $\delta(C)$ 127.8 (*d*), 139.7 (*s*). The 1H - and ^{13}C -NMR spectra of **1** were almost superimposable with those of



	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
1	H	Glc	CH ₂ OH	H	Me	OH	H
2	H	GlcA	CH ₂ OH	H	Me	OH	H
3	OH	(6'-BuO)GlcA	CH ₂ OH	Glc	Me	H	H
4	H	Glc ¹ → ⁴ (6'-BuO)GlcA	Me	Glc	H	H	Me
5	H	Rha ¹ → ² Glc	CH ₂ OH	H	Me	OH	H
6	H	Ara ³ ← ¹ Glc	CH ₂ OH	Glc	Me	H	H
7	H	Glc ² ← ¹ Glc	CH ₂ OH	H	Me	OH	H
8	H	Glc ² ← ¹ Glc	CH ₂ OH	Glc	Me	OH	H
9	H	Glc	CH ₂ OH	H	H	H	Me
10	H	Ara ³ ← ¹ Glc	CH ₂ OH	H	Me	OH	H
11	H	GlcA(6'-OMe)	CH ₂ OH	Glc	Me	H	H
12	H	GlcA	Me	Glc	Me	H	H
13	H	GlcA(6'-OMe)	Me	Glc	Me	H	H
14	H	Ara ² ← ¹ Rha	CH ₂ OH	Glc	H	H	Me
15	H	Ara ³ ← ¹ Glc	CH ₂ OH	Glc	H	H	Me
16	H	GlcA	CH ₂ OH	Glc	Me	H	H

randiasaponin II (**10**) for the aglycon moiety [11], corresponding to rotundic acid, and the main difference was observed for the signals of the sugar moiety. The NMR spectra of the sugar unit indicated it to be a D-glucose, which was confirmed by acid hydrolysis and GC analysis of the thiazolidine derivative. The correlation between the anomeric H-atom signal of the D-glucose at $\delta(\text{H})$ 5.08 ($d, J = 8.0$) and the C-atom signal at $\delta(\text{C})$ 82.0 (C(3) of aglycon) in the HMBC spectrum suggested that the glucose was attached to C(3) of the aglycon. Meanwhile, the anomeric configuration of D-glucose was deduced to be β from the coupling constant value observed for the H–C(1') ($J = 8.0$). Hence, the structure of **1** was established as (3 β)-3-(β -D-glucopyranosyloxy)-19,23-dihydroxyurs-12-en-28-oic acid, and named ilexpernoside C.

Compound **2**, a colorless gum, exhibited a $[M + \text{Na}]^+$ peak at m/z 687.3716 by HR-ESI-MS, which was consistent with the molecular formula C₃₆H₅₆O₁₁, indicating 9 degrees of unsaturation. The ¹H- and ¹³C-NMR spectra of **2** displayed many similarities with those of **1**, except for the sugar moiety, indicating that **1** and **2** have the same aglycon (rotundic acid). The sugar moiety was elucidated to be a D-glucuronic acid (GlcA) by comparison of the NMR signals for the sugar unit of **2** with the corresponding signals of cynarasaponin C (**12**) [12], a saponin isolated from *I. pernyi* as well. Acid hydrolysis, together with GC analysis, confirmed this elucidation. The β -linkage of the glucuronic acid moiety was suggested by the J value of the anomeric H-atom ($J = 7.5$). Thus, the structure of **2** was established as (3 β)-19,23,28-trihydroxy-28-

Table 1. ^{13}C -NMR Data for the Aglycons of **1–8** (125 MHz, $\text{C}_5\text{D}_5\text{N}$). δ in ppm.

Position	1	2	3	4	5	6	7	8
1	38.4	38.5	47.5	38.6	39.1	39.0	38.6	38.7
2	25.6	25.9	66.7	26.1	26.3	26.1	25.8	25.8
3	82.0	82.0	88.1	89.2	81.4	81.7	82.7	82.7
4	43.2	43.3	44.6	39.5	43.4	43.4	43.3	43.4
5	47.4	47.4	47.0	55.7	47.7	47.3	48.0	48.0
6	18.1	18.2	18.0	18.4	18.2	18.0	18.3	18.3
7	32.9	33.1	33.0	33.1	33.1	33.0	33.1	33.1
8	40.1	40.2	40.1	39.9	40.2	40.0	40.2	40.4
9	47.5	47.6	48.0	48.0	47.8	48.0	47.6	47.7
10	36.6	36.7	37.6	36.9	36.7	36.7	36.7	36.7
11	23.8	23.9	23.6	23.4	23.9	23.6	23.9	24.0
12	127.8	127.9	126.0	122.8	127.9	126.0	127.9	128.3
13	139.7	139.8	138.3	144.1	139.8	138.3	139.9	139.2
14	41.8	42.0	42.4	42.1	42.0	42.3	42.0	42.0
15	29.1	29.2	28.5	28.2	29.2	28.6	29.2	29.1
16	26.1	26.2	24.5	23.7	26.3	24.5	26.2	26.0
17	48.0	48.2	48.2	47.0	48.2	48.2	48.1	48.5
18	54.3	54.5	53.2	41.7	54.5	53.2	54.5	54.3
19	72.4	72.5	39.2	46.2	72.5	38.8	72.5	72.5
20	42.1	42.2	39.0	30.8	42.2	39.2	42.2	42.0
21	26.7	26.8	30.7	34.0	27.0	30.6	26.8	26.6
22	38.3	38.4	36.7	32.5	38.4	36.7	38.4	37.6
23	64.4	64.3	63.4	28.0	63.8	64.1	65.0	65.0
24	13.4	13.5	14.6	16.9	14.0	13.5	13.3	13.3
25	15.7	16.0	17.3	15.5	16.0	21.1	15.9	16.1
26	17.3	17.1	17.5	17.4	17.1	16.2	17.1	17.3
27	24.6	24.6	23.6	26.5	24.6	23.6	24.6	24.5
28	180.5	180.6	176.1	176.4	180.5	176.1	180.5	176.9
29	26.8	27.0	17.6	33.1	26.8	17.2	27.0	26.9
30	16.5	16.7	21.2	23.6	16.7	17.6	16.7	16.6

oxours-12-en-3-yl β -D-glucopyranosiduronic acid, for which the trivial name ilexpernoside **D** was proposed.

Compound **3** was obtained as a white, amorphous powder. The positive HR-ESI-MS spectrum exhibited a $[M + \text{Na}]^+$ peak at m/z 905.4835, corresponding to the molecular formula $\text{C}_{46}\text{H}_{74}\text{O}_{16}$. The ^1H -NMR spectrum (Table 3) indicated the presence of four Me *singlets* at $\delta(\text{H})$ 0.96, 1.00, 1.06, 1.12, two Me *doublets* at $\delta(\text{H})$ 0.84 ($J = 5.5$) and 0.88 ($J = 6.0$), two oxygenated CH groups at $\delta(\text{H})$ 4.19–4.21 (m , H–C(2)) and 4.22–4.25 (m , H–C(3)), an oxygenated CH_2 group at $\delta(\text{H})$ 3.66, 4.46 (AB , $J = 11.0$, $\text{CH}_2(23)$), and one olefinic H-atom at $\delta(\text{H})$ 5.38 (t , $J = 3.0$, H–C(12)) in the aglycon moiety. The ^{13}C -NMR spectrum for the aglycon moiety of **3** (Table 1) exhibited the signals due to one ester CO group at $\delta(\text{C})$ 176.1 (s), one oxygenated CH_2 group at $\delta(\text{C})$ 63.4 (t), two oxygenated CH groups at $\delta(\text{C})$ 66.7 (d), 88.1 (d), and two olefinic C-atoms at $\delta(\text{C})$ 126.0 (d) and 138.3 (s). The data above indicated that compound **3** may have the same aglycon as ilekudinoside **C** [4]. Comparison of the NMR signals of the sugar moiety of **3** with those of 1- O -[(3β)-3-[(6-butyl- β -D-glucopyranuronosyl)oxy]-28-

Table 2. ^{13}C -NMR Data for the Sugar Moieties of **1–8** (125 MHz, $\text{C}_5\text{D}_5\text{N}$). δ in ppm.

Position	1	2	3	4	5	6	7	8
3- <i>O</i> -Sugar	Glc ^{a)}	GlcA ^{a)}	GlcA	GlcA	Glc	Ara ^{a)}	Glc	Glc
1	105.6	106.1	105.8	107.0	104.5	106.4	103.7	103.7
2	75.6	75.3	75.1	74.6	77.2	71.8	83.9	84.0
3	78.4	78.0	77.8	76.1	79.8	84.0	78.3	78.4
4	71.4	73.3	72.9	82.4	72.0	69.1	71.1	71.1
5	78.0	77.7	76.9	75.3	77.9	66.9	77.9	78.0
6	62.6	173.0	169.7	169.5	62.7		62.6	62.6
Ester moiety COOBu								
1			65.1	65.5				
2			30.7	30.7				
3			19.1	19.3				
4			13.6	13.8				
Terminal sugar				Glc	Rha ^{a)}	Glc	Glc	Glc
1				104.9	101.4	106.2	105.8	105.9
2				74.8	72.3	75.6	76.7	76.7
3				78.2	72.4	78.2	77.9	78.0
4				71.6	74.0	71.4	71.2	71.2
5				78.5	69.4	78.6	78.2	78.2
6				62.1	18.5	62.5	62.4	62.4
28- <i>O</i> -Sugar			Glc	Glc		Glc		Glc
1			95.6	95.7		95.6		95.7
2			74.0	74.1		73.9		74.0
3			78.8	78.9		78.7		78.8
4			71.1	71.0		70.9		71.1
5			79.1	79.4		79.1		79.1
6			62.2	62.5		62.1		62.2

^{a)} Glc = β -D-glucopyranose; GlcA = β -D-glucuronopyranose; Ara = α -L-arabinopyranose; Rha = α -L-rhamnopyranose.

oxoolean-12-en-28-yl]- β -D-glucopyranose permitted the assignment of the sugar moiety of **3** as a D-glucuronyl moiety esterified at C(6') with BuOH, and a D-glucose [13]. This assignment was confirmed by acid hydrolysis and GC analysis. Furthermore, the sites of glycosylation and the location of the *O*-Bu group were also established by HMBC experiments showing long-range correlations between H–C(1') of the D-glucuronyl moiety at $\delta(\text{H})$ 5.23 (*d*, $J = 7.5$) and C(3) of aglycon at $\delta(\text{C})$ 88.1, H–C(1'') of the D-glucose ($\delta(\text{H})$ 6.24 (*d*, $J = 8.0$) and C(28) ($\delta(\text{C})$ 176.1) of the aglycon, and CH₂(1'') of the butyl ($\delta(\text{H})$ 4.14–4.17 (*m*) and 4.17–4.21 (*m*)) and C(6') ($\delta(\text{C})$ 169.7) of the D-glucuronyl moiety. Thus, the structure of **3** was assigned as 1-*O*-{(2 α ,3 β)-3-[(6-butyl- β -D-glucopyranuronosyl)oxy]-2,23-dihydroxy-28-oxours-12-en-28-yl]- β -D-glucopyranose, and named ilexpernoside E.

Compound **4**, a white and amorphous powder, was assigned the molecular formula C₅₂H₈₄O₁₉ (HR-ESI-MS m/z 1035.5496, [$M + \text{Na}$]⁺). The ¹H- and ¹³C-NMR spectra of **4** were almost superimposable with those of 1-*O*-(3 β)-3-[[4-*O*-(β -D-glucopyranosyl)- β -D-glucopyranuronosyl]oxy]-28-oxoolean-12-en-28-yl]- β -D-glucopyranose except that **4**

Table 3. ¹H-NMR Data of **1–4** (500 MHz, C₅D₅N). δ in ppm, *J* in Hz.

Position	1	2	3	4
Triterpene moiety				
2	1.82–1.86 (<i>m</i>), 2.20–2.24 (<i>m</i>)	1.95–1.98 (<i>m</i>), 2.23–2.26 (<i>m</i>)	4.19–4.21 (<i>m</i>)	1.82–1.85 (<i>m</i>), 2.04–2.07 (<i>m</i>)
3	4.21 (<i>dd</i> , <i>J</i> = 12.0, 4.5)	4.30–4.33 (<i>m</i>)	4.22–4.25 (<i>m</i>)	3.27 (<i>dd</i> , <i>J</i> = 11.7, 3.9)
12	5.54 (<i>br. s</i>)	5.55 (<i>br. s</i>)	5.38 (<i>t</i> , <i>J</i> = 3.0)	5.40 (<i>br. s</i>)
18	2.98 (<i>s</i>)	3.00 (<i>s</i>)	2.47 (<i>d</i> , <i>J</i> = 11.5)	3.18 (<i>dd</i> , <i>J</i> = 13.3, 3.8)
23	3.66, 4.28 (<i>AB</i> , <i>J</i> = 11.0)	3.68, 4.32 (<i>AB</i> , <i>J</i> = 10.0)	3.66, 4.46 (<i>AB</i> , <i>J</i> = 11.0)	1.25 (<i>s</i>)
24	0.91 (<i>s</i>)	0.92 (<i>s</i>)	0.96 (<i>s</i>)	0.94 (<i>s</i>)
25	0.88 (<i>s</i>)	0.88 (<i>s</i>)	1.00 (<i>s</i>)	0.80 (<i>s</i>)
26	1.04 (<i>s</i>)	1.06 (<i>s</i>)	1.12 (<i>s</i>)	1.07 (<i>s</i>)
27	1.63 (<i>s</i>)	1.67 (<i>s</i>)	1.06 (<i>s</i>)	1.25 (<i>s</i>)
29	1.38 (<i>s</i>)	1.39 (<i>s</i>)	0.88 (<i>d</i> , <i>J</i> = 6.0)	0.89 (<i>s</i>)
30	1.06 (<i>d</i> , <i>J</i> = 6.5)	1.08 (<i>d</i> , <i>J</i> = 6.5)	0.84 (<i>d</i> , <i>J</i> = 5.5)	0.86 (<i>s</i>)
3- <i>O</i> -Sugar	Glc ^a)	GlcA ^a)	GlcA	GlcA
1	5.08 (<i>d</i> , <i>J</i> = 8.0)	5.23 (<i>d</i> , <i>J</i> = 7.5)	5.23 (<i>d</i> , <i>J</i> = 7.5)	4.97 (<i>d</i> , <i>J</i> = 7.7)
2	3.98 (<i>t</i> , <i>J</i> = 8.0)	4.11 (<i>t</i> , <i>J</i> = 8.0)	4.10–4.13 (<i>m</i>)	4.09 (<i>t</i> , <i>J</i> = 8.5)
3	4.13 (<i>t</i> , <i>J</i> = 9.0)	4.21 (<i>t</i> , <i>J</i> = 9.0)	4.08–4.11 (<i>m</i>)	4.29–4.32 (<i>m</i>)
4	4.15 (<i>t</i> , <i>J</i> = 9.5)	4.54 (<i>t</i> , <i>J</i> = 10.0)	4.37–4.40 (<i>m</i>)	4.52 (<i>t</i> , <i>J</i> = 9.6)
5	3.85–3.88 (<i>m</i>)	4.56 (<i>t</i> , <i>J</i> = 9.5)	4.42–4.45 (<i>m</i>)	4.67 (<i>d</i> , <i>J</i> = 9.8)
6	4.32 (<i>dd</i> , <i>J</i> = 12.0, 5.0), 4.46 (<i>br. d</i> , <i>J</i> = 10.5)			
Ester moiety COOBu				
1			4.14–4.17 (<i>m</i>), 4.17–4.21 (<i>m</i>)	4.28–4.31 (<i>m</i>), 4.40–4.43 (<i>m</i>)
2			1.51–1.54 (<i>m</i>)	1.59–1.62 (<i>m</i>)
3			1.24–1.27 (<i>m</i>)	1.27–1.31 (<i>m</i>)
4			0.71 (<i>t</i> , <i>J</i> = 7.5)	0.74 (<i>t</i> , <i>J</i> = 7.3)
Terminal sugar				
1				Glc 5.10 (<i>d</i> , <i>J</i> = 7.9)
2				3.98–4.02 (<i>m</i>)
3				4.16–4.19 (<i>m</i>)
4				4.13–4.16 (<i>m</i>)
5				3.96–3.99 (<i>m</i>)
6				4.25–4.29 (<i>m</i>), 4.44–4.47 (<i>m</i>)
28- <i>O</i> -Sugar				
1			Glc	Glc
2			6.24 (<i>d</i> , <i>J</i> = 8.0)	6.33 (<i>d</i> , <i>J</i> = 8.0)
3			4.16–4.19 (<i>m</i>)	4.20 (<i>t</i> , <i>J</i> = 8.5)
4			4.25 (<i>t</i> , <i>J</i> = 8.5)	4.26–4.29 (<i>m</i>)
5			4.33 (<i>t</i> , <i>J</i> = 9.0)	4.37 (<i>t</i> , <i>J</i> = 9.1)
6			3.97–4.01 (<i>m</i>)	4.00–4.03 (<i>m</i>)
			4.35–4.38 (<i>m</i>), 4.40–4.43 (<i>m</i>)	4.37–4.41 (<i>m</i>), 4.53–4.56 (<i>m</i>)

^a) Glc = β -D-glucopyranose; GlcA = β -D-glucuronopyranose.

showed additional *O*-butyl signals ($\delta(\text{H})$ 0.74 (*t*, $J = 7.3$); $\delta(\text{C})$ 65.5 (*t*), 30.7 (*t*), 19.3 (*t*) and 13.8 (*q*)) [14], suggesting that **4** is a butyl ester derivative of the latter compound. The sugar moieties were confirmed by acid hydrolysis and GC analysis. Location of the *O*-Bu group and the sites of glycosylation were also confirmed by HMBC experiments, showing long-range correlations between $\text{CH}_2(1''')$ of the butyl group ($\delta(\text{H})$ 4.28–4.31 (*m*) and 4.40–4.43 (*m*)) and C(6') ($\delta(\text{C})$ 169.5) of the *D*-glucuronyl moiety, H–C(1') of the *D*-glucuronyl moiety ($\delta(\text{H})$ 4.97 (*d*, $J = 7.7$)) and C(3) ($\delta(\text{C})$ 89.2) of aglycon, H–C(1'') of the *D*-glucose ($\delta(\text{H})$ 5.10 (*d*, $J = 7.9$)) and C(4') ($\delta(\text{C})$ 82.4) of *D*-glucuronyl moiety, H–C(1''') of the *D*-glucose ($\delta(\text{H})$ 6.33 (*d*, $J = 8.0$)) and C(28) ($\delta(\text{C})$ 176.4) of the aglycon. Therefore, the structure of **4** was determined as 1-*O*-[(3 β)-3-[[6-butyl-4-*O*-(β -*D*-glucopyranosyl)- β -*D*-glucopyranuronosyl]oxy]-28-oxoolean-12-en-28-yl]- β -*D*-glucopyranose, for which the trivial name ilexpernoside F was given.

Compound **5**, obtained as a colorless gum, showed a quasimolecular-ion peak ($[M + H]^+$) at m/z 797.4675 in the HR-ESI-MS, corresponding to the molecular formula $\text{C}_{42}\text{H}_{68}\text{O}_{14}$. Analysis of the ^1H - and ^{13}C -NMR spectroscopic data indicated that **5** possessed the same aglycon as that of **1** and **2**, but differed in a sugar moiety. The ^{13}C -NMR chemical shift of C(3) ($\delta(\text{C})$ 81.4) indicated that a sugar moiety was attached to C(3) of the aglycon. Acid hydrolysis of **5** afforded *D*-glucose and *L*-rhamnose. The presence of two anomeric H-atom signals (*Table 4*) at $\delta(\text{H})$ 5.14 (*d*, $J = 8.0$) and 6.54 (*d*, $J = 1.5$), together with the two corresponding C-atom signals at $\delta(\text{C})$ 104.5 and 101.4, indicated that **5** is a saponin with a disaccharide of *D*-glucose and *L*-rhamnose. The linkage and the anomeric configuration of the sugar units agreed with the disaccharide found in ilekudinoside K [8]. Hence, compound **5** was elucidated as (3 β)-3-[[2-*O*-(6-deoxy- α -*L*-mannopyranosyl)- β -*D*-glucopyranosyl]oxy]-19,23-dihydroxyurs-12-en-28-oic acid, named ilexpernoside G.

Compound **6**, a colorless gum, showed the molecular formula $\text{C}_{47}\text{H}_{76}\text{O}_{18}$ (HR-ESI-MS m/z 929.5082 $[M + H]^+$). Acid hydrolysis afforded *D*-glucose and *L*-arabinose. The ^1H -NMR spectrum (*Table 4*) indicated the presence of four Me *singlets* at $\delta(\text{H})$ 0.84, 0.89, 0.93, and 1.10, two Me *doublets* at $\delta(\text{H})$ 0.89 ($J = 6.5$) and 1.12 ($J = 6.0$), one oxygenated CH group at $\delta(\text{H})$ 4.21–4.24 (*m*, H–C(3)), one oxygenated CH_2 group at $\delta(\text{H})$ 3.67 and 4.28 (*AB*, $J = 10.5$, $\text{CH}_2(23)$), and one olefinic H-atom at $\delta(\text{H})$ 5.41 (*br. s*, H–C(12)) in the aglycon moiety. The ^{13}C -NMR spectrum for the aglycon moiety of **6** (*Table 1*) exhibited signals due to one ester CO group at $\delta(\text{C})$ 176.1 (*s*), one oxygenated CH_2 group at $\delta(\text{C})$ 64.1 (*t*), one oxygenated CH group at $\delta(\text{C})$ 81.7 (*d*), and two olefinic C-atoms at $\delta(\text{C})$ 126.0 (*d*) and 138.3 (*s*). The data above indicated that **6** has the same aglycon as 1-*O*-[(3 β)-23-hydroxy-3-[(6-methyl- β -*D*-glucopyranuronosyl]oxy]-28-oxours-12-en-28-yl]- β -*D*-glucopyranose (**11**) [12]. Detailed ^1H - and ^{13}C -NMR data analysis suggested that **6** possessed the same sugar moiety as 1-*O*-[(3 β)-3-[[3-*O*-(β -*D*-glucopyranosyl)- α -*L*-arabinopyranosyl]oxy]-23-hydroxy-28-oxoolean-12-en-28-yl]- β -*D*-glucopyranose (**15**), which was also isolated from *I. pernyi* [15]. Confirmation was given from the HMBC correlation signals between H–C(1') ($\delta(\text{H})$ 4.93 (*d*, $J = 7.5$)) of arabinose and C(3) ($\delta(\text{C})$ 81.7) of the aglycon, H–C(1'') ($\delta(\text{H})$ 5.27 (*d*, $J = 8.0$)) of the terminal glucose and C(3') ($\delta(\text{C})$ 84.0) of the arabinose, and H–C(1''') ($\delta(\text{H})$ 6.23 (*d*, $J = 8.0$)) of glucose and C(28) ($\delta(\text{C})$ 176.1) of the aglycon. Thus, compound **6** was elucidated as 1-*O*-[(3 β)-3-[[3-*O*-(β -*D*-glucopyranosyl)- α -*L*-arabinopyranosyl]oxy]-23-hydroxy-28-oxours-12-en-28-yl]- β -*D*-glucopyranose, named ilexpernoside H.

Table 4. ¹H-NMR Data of **5–8** (500 MHz, C₅D₅N). δ in ppm, *J* in Hz.

Position	5	6	7	8
Triterpene moiety				
2	1.95–1.98 (<i>m</i>), 2.31–2.34 (<i>m</i>)	1.94–1.97 (<i>m</i>), 2.17–2.21 (<i>m</i>)	1.88–1.92 (<i>m</i>), 2.20–2.23 (<i>m</i>)	1.92–1.95 (<i>m</i>), 2.14–2.17 (<i>m</i>)
3	4.25–4.28 (<i>m</i>)	4.21–4.24 (<i>m</i>)	4.11–4.15 (<i>m</i>)	4.10–4.13 (<i>m</i>)
12	5.55 (<i>t</i> , <i>J</i> = 3.5)	5.41 (br. <i>s</i>)	5.55 (br. <i>s</i>)	5.51 (<i>t</i> , <i>J</i> = 3.5)
18	3.00 (<i>s</i>)	2.47 (<i>d</i> , <i>J</i> = 11.5)	3.00 (<i>s</i>)	2.89 (<i>s</i>)
23	3.71, 4.24 (<i>AB</i> , <i>J</i> = 10.5)	3.67, 4.28 (<i>AB</i> , <i>J</i> = 10.5)	3.72, 4.33 (<i>AB</i> , <i>J</i> = 11.0)	3.73 (<i>d</i> , <i>J</i> = 11.0), 4.32–4.35 (<i>m</i>)
24	1.11 (<i>s</i>)	0.89 (<i>s</i>)	1.06 (<i>s</i>)	1.08 (<i>s</i>)
25	0.91 (<i>s</i>)	0.84 (<i>s</i>)	0.89 (<i>s</i>)	0.94 (<i>s</i>)
26	1.07 (<i>s</i>)	0.93 (<i>s</i>)	1.06 (<i>s</i>)	1.18 (<i>s</i>)
27	1.65 (<i>s</i>)	1.10 (<i>s</i>)	1.64 (<i>s</i>)	1.60 (<i>s</i>)
29	1.40 (<i>s</i>)	0.89 (<i>d</i> , <i>J</i> = 6.5)	1.39 (<i>s</i>)	1.35 (<i>s</i>)
30	1.08 (<i>d</i> , <i>J</i> = 6.5)	1.12 (<i>d</i> , <i>J</i> = 6.0)	1.08 (<i>d</i> , <i>J</i> = 6.5)	1.03 (<i>d</i> , <i>J</i> = 6.5)
3- <i>O</i> -Sugar	Glc ^a)	Ara ^a)	Glc	Glc
1	5.14 (<i>d</i> , <i>J</i> = 8.0)	4.93 (<i>d</i> , <i>J</i> = 7.5)	5.05 (<i>d</i> , <i>J</i> = 6.5)	5.06 (<i>d</i> , <i>J</i> = 7.5)
2	4.24–4.27 (<i>m</i>)	4.52–4.55 (<i>m</i>)	4.12–4.15 (<i>m</i>)	4.12–4.15 (<i>m</i>)
3	4.08 (<i>t</i> , <i>J</i> = 8.5)	4.04–4.07 (<i>m</i>)	4.17–4.21 (<i>m</i>)	4.15–4.18 (<i>m</i>)
4	4.13 (<i>t</i> , <i>J</i> = 9.0)	4.33–4.36 (<i>m</i>)	4.14–4.17 (<i>m</i>)	4.31–4.35 (<i>m</i>)
5	3.77–3.80 (<i>m</i>)	3.58–3.61 (<i>m</i>), 4.10–4.13 (<i>m</i>)	3.75–3.78 (<i>m</i>)	3.76–3.79 (<i>m</i>)
6	4.31–4.34 (<i>m</i>), 4.44–4.47 (<i>m</i>)		4.27–4.30 (<i>m</i>), 4.45 (br. <i>d</i> , <i>J</i> = 10.0)	4.30–4.48 (<i>m</i>)
Terminal sugar	Rha ^a)	Glc	Glc	Glc
1	6.54 (<i>d</i> , <i>J</i> = 1.5)	5.27 (<i>d</i> , <i>J</i> = 8.0)	5.35 (<i>d</i> , <i>J</i> = 7.5)	5.36 (<i>d</i> , <i>J</i> = 7.5)
2	4.75–4.78 (<i>m</i>)	3.97–4.01 (<i>m</i>)	4.07–4.10 (<i>m</i>)	4.08–4.11 (<i>m</i>)
3	4.64–4.67 (<i>m</i>)	4.22–4.25 (<i>m</i>)	4.17–4.20 (<i>m</i>)	4.17–4.21 (<i>m</i>)
4	4.28–4.32 (<i>m</i>)	4.17–4.21 (<i>m</i>)	4.27 (<i>t</i> , <i>J</i> = 9.0)	4.11–4.13 (<i>m</i>)
5	4.77–4.80 (<i>m</i>)	3.93–3.96 (<i>m</i>)	3.85–3.89 (<i>m</i>)	3.87–3.91 (<i>m</i>)
6	1.67 (<i>d</i> , <i>J</i> = 6.0)	4.30–4.33 (<i>m</i>), 4.47–4.50 (<i>m</i>)	4.40 (<i>dd</i> , <i>J</i> = 11.0, 3.5), 4.45 (br. <i>d</i> , <i>J</i> = 10.0)	4.30–4.48 (<i>m</i>)
28- <i>O</i> -Sugar		Glc		Glc
1		6.23 (<i>d</i> , <i>J</i> = 8.0)		6.27 (<i>d</i> , <i>J</i> = 8.0)
2		4.16 (<i>t</i> , <i>J</i> = 8.5)		4.20 (<i>t</i> , <i>J</i> = 8.5)
3		4.23–4.26 (<i>m</i>)		4.25–4.29 (<i>m</i>)
4		4.34 (<i>t</i> , <i>J</i> = 9.1)		4.28 (<i>t</i> , <i>J</i> = 9.1)
5		3.95–3.98 (<i>m</i>)		4.01–4.04 (<i>m</i>)
6		4.35–4.39 (<i>m</i>), 4.39–4.42 (<i>m</i>)		4.30–4.48 (<i>m</i>)

^a) Glc = β-D-glucopyranose; Ara = α-L-arabinopyranose; Rha = α-L-rhamnopyranose.

Compound **7**, obtained as a white and amorphous powder, was assigned the molecular formula as C₄₂H₆₈O₁₅, determined from the quasimolecular-ion peak ([*M* + H]⁺) at *m/z* 813.4630 in the HR-ESI-MS. Its spectroscopic features indicated **7** to be another rotundic acid disaccharide, differing in the sugar moiety from **1**, **2**, and **5**. Acid hydrolysis of **7** afforded D-glucose only. Careful NMR data analysis indicated that **7** had the same disaccharide chain as ilekudinoside N [8]. The sites of glycosylation were

confirmed by the HMBC correlation signals between H–C(1') ($\delta(\text{H})$ 5.05 ($d, J = 6.5$)) of inner glucose and C(3) ($\delta(\text{C})$ 82.7) of the aglycon, and H–C(1'') ($\delta(\text{H})$ 5.35 ($d, J = 7.5$)) of terminal glucose and C(2') ($\delta(\text{C})$ 83.9) of the inner glucose. Therefore, the structure of **7** was determined as (3 β)-3-[[2-*O*-(β -D-glucopyranosyl)- β -D-glucopyranosyl]oxy]-19,23-dihydroxyurs-12-en-28-oic acid, and named ilexpernoside I.

Compound **8** was obtained as a white, amorphous powder. The HR-ESI-MS showed a $[M + \text{H}]^+$ ion at m/z 975.5157, in accordance with an empirical molecular formula of $\text{C}_{48}\text{H}_{78}\text{O}_{20}$. The spectroscopic data indicated that **8** was a further rotundic acid trisaccharide, differing in the sugar units from those of **1**, **2**, and **5**. Acid hydrolysis of **8** afforded only D-glucose. The ^1H - and ^{13}C -NMR spectra of **8** were superimposable with those of **7**, except for an additional D-glucose. The long-range correlation between H–C(1''') ($\delta(\text{H})$ 6.27 ($d, J = 8.0$)) of the additional glucose and C(28) ($\delta(\text{C})$ 176.9) of the aglycon in HMBC indicated that the additional D-glucose was attached to C(28) of the aglycon. Hence, compound **8** was elucidated as 1-*O*-[(3 β)-3-[[2-*O*-(β -D-glucopyranosyl)- α -D-glucopyranosyl]oxy]-23-hydroxy-28-oxours-12-en-28-yl]- β -D-glucopyranose, for which the name ilexpernoside J was given.

The natural occurrence of triterpene saponins possessing butyl-esterified glucuronic acid in the sugar portion is extremely rare [13][16]. The new compounds **3** and **4** are regarded as genuine natural products and not artifacts formed during extraction by BuOH. Such statement was confirmed by an additional experiment in which cynarasaponin C, a known compound isolated from *I. pernyi*, was treated with a slightly acidic (0.001 % (w/v) H_2SO_4) BuOH solution (80° for 2 h) [16], resulting in the detection of only the unreacted cynarasaponin C.

The eight known compounds were identified as (3 β)-3-(β -D-glucopyranosyloxy)-hederagenin (**9**) [17], randiasaponin II (**10**) [11], 1-*O*-[(3 β)-23-hydroxy-3-[(6-methyl- β -D-glucopyranuronosyl)oxy]-28-oxours-12-en-28-yl]- β -D-glucopyranose (**11**) [12], cynarasaponin C (**12**) [12], 1-*O*-[(3 β)-3-[(6-methyl- β -D-glucopyranuronosyl)oxy]-28-oxours-12-en-28-yl]- β -D-glucopyranose (**13**) [12], 1-*O*-[(3 β)-3-[[2-*O*-(6-deoxy- α -L-mannopyranosyl)- α -L-arabinopyranosyl]oxy]-23-hydroxy-28-oxoolean-12-en-28-yl]- β -D-glucopyranose (**14**) [18], 1-*O*-[(3 β)-3-[[3-*O*-(β -D-glucopyranosyl)- α -L-arabinopyranosyl]oxy]-23-hydroxy-28-oxoolean-12-en-28-yl]- β -D-glucopyranose (**15**) [15], and cynarasaponin E (**16**) [12], on the basis of their NMR and MS data, and by comparison with the literature data. All the eight known compounds were found for the first time in this plant species.

This work was supported by the *National Natural Science Foundation of China* (No. 30672608) and the *Program for Changjiang Scholars and Innovative Team in University* (No. 985-2-063-112).

Experimental Part

General. Column chromatography (CC): silica gel *H* (SiO_2 ; 200–300 mesh; *Qingdao Marine Chemical Industry*), *ODS* gel (25–40 μm ; *Merck*), and *D101* porous polymer resin (*Tianjin Chemical Industry*). Semi-prep. HPLC: *Waters 600* Pump with *600* controller, *Waters C18 Nova-Pak* column (300 \times 7.8 mm, 5 μm), with *ELSD* detector (*Alltech*); flow rate, 2.5 ml/min. GC: *Agilent 6890N* gas chromatograph; capillary column (28 m \times 0.32 mm i.d.; *HP-5*); *FID* detector, operated at 260° (column temp. 180°); N_2 as carrier gas (40 ml/min). Optical rotations: *Perkin-Elmer 243B* digital polarimeter. IR spectra: *NEXUS-470 FTIR* (*Nicolet*) spectrometer; KBr pellets; in cm^{-1} . NMR Spectra: *Varian Inova-*

500 and Varian Unity-500 instruments; at 500 (^1H) or 125 MHz (^{13}C) in $\text{C}_5\text{D}_5\text{N}$ at r.t.; δ in ppm rel. to TMS, J in Hz. ESI-MS (positive): QSTAR (ABI, USA) mass spectrometer; in m/z . HR-ESI-MS (positive): Bruker APEX II FT-ICR-MS mass spectrometer; in m/z .

Plant Material. The leaves of *Ilex pernyi* were collected by Dr. S.-X. Zhou in April 2005 at the Nature Protect Area of Shennongjia, Hubei Province, China. The identification of the plant was performed by Prof. P.-F. Tu, Peking University. A voucher specimen was deposited with the herbarium of Peking University Modern Research Center for Traditional Chinese Medicine (MEC0504).

Extraction and Isolation. The air-dried and powdered leaves (15 kg) of *I. pernyi* were extracted with 70% EtOH ($3 \times 80\text{ l}$) at 60° for 2 h. After removal of the solvent under vacuum, the residue was suspended in H_2O (12 l) and partitioned successively with AcOEt ($3 \times 15\text{ l}$) and BuOH ($3 \times 15\text{ l}$) after being defatted with petroleum ether (PE; $2 \times 10\text{ l}$). 400 g BuOH extract (490 g in total) was subjected to CC (D101 porous polymer resin) and eluted with H_2O and 10, 30, 50, 70, 95% aq. EtOH, resp. The fractions eluted with 50% and 70% aq. EtOH (97 g) were subjected to CC (SiO_2 , $\text{CHCl}_3/\text{MeOH}/\text{H}_2\text{O}$ 10:1:0 \rightarrow 1:1:0.1) to afford 6 subfractions (Fr. 1–6). Fr. 2 was subjected to CC (ODS, 70% aq. MeOH) to afford hederagenin 3-*O*- β -D-glucopyranoside (**9**, 14 mg) and Fr. 2-1. Fr. 2-1 was purified by semi-prep. HPLC (MeOH/0.05% aq. TFA 3:2) to afford **1** (25 mg, t_{R} : 13.2 min). Fr. 3 was subjected to CC (ODS, MeOH/ H_2O , 2:3 \rightarrow 4:1) to afford Fr. 3-1–3-5. Each fraction was separated by semi-prep. HPLC (MeOH/ H_2O 3:2 for Fr. 3-1; MeOH/0.05% aq. TFA 67:33 for Fr. 3-2; MeOH/0.05% aq. TFA 29:21 for Fr. 3-3; MeOH/0.05% aq. TFA 13:7 for Fr. 3-4 and 3-5) to yield randiasaponin II (**10**, 10 mg, t_{R} : 22.4 min), 1-*O*-[(3 β)-23-hydroxy-[(6-methyl- β -D-glucopyranuronosyl)oxy]-28-oxours-12-en-28-yl]- β -D-glucopyranose (**11**, 11 mg, t_{R} : 17.6 min), **2** (6 mg, t_{R} : 19.7 min), cynarasaponin C (**12**, 13 mg, t_{R} : 30.8 min) and **3** (10 mg, t_{R} : 27.4 min), resp. Fr. 4 was subjected to CC (ODS, 80% aq. MeOH) to afford **4** (8 mg) and Fr. 4-1, which was further purified by CC (SiO_2 , $\text{CHCl}_3/\text{MeOH}/\text{H}_2\text{O}$ 10:1:0.1) to give ursolic acid 1-*O*-[(3 β)-3-[(6-methyl- β -D-glucopyranuronosyl)oxy]-28-oxours-12-en-28-yl]- β -D-glucopyranose (**13**, 12 mg). Fr. 5 was subjected to CC (ODS, MeOH/ H_2O 3:2 \rightarrow 4:1) to afford Fr. 5-1–5-4. Each fraction was separated by semi-prep. HPLC (MeOH/0.05% aq. TFA 3:2 for Fr. 5-1, 5-2, and 5-3; MeOH/0.05% aq. TFA 53:47 for Fr. 5-4) to yield **5** (70 mg, t_{R} : 17.0 min), 1-*O*-[(3 β)-3-[[2-*O*-(6-deoxy- α -L-mannopyranosyl)- α -L-arabinopyranosyloxy]-23-hydroxy-28-oxoolean-12-en-28-yl]- β -D-glucopyranose (**14**, 20 mg, t_{R} : 43.0 min), **6** (15 mg, t_{R} : 35.2 min), and 1-*O*-[(3 β)-3-[[3-*O*- β -D-glucopyranosyl- α -L-arabinopyranosyl]oxy]-23-hydroxy-28-oxoolean-12-en-28-yl]- β -D-glucopyranose (**15**, 20 mg, t_{R} : 42.4 min), **7** (25 mg, t_{R} : 26.2 min), and cynarasaponin E (**16**, 15 mg, t_{R} : 30.0 min), resp. Fr. 6 was subjected to CC (ODS, 40% aq. MeOH) to give Fr. 6-1, which was further purified by semi-prep. HPLC (MeOH/0.05% aq. TFA 23:27) to afford **8** (87 mg, t_{R} : 28.0 min).

Acid Hydrolysis. Each saponin (4 mg) was heated in 4 ml of 10% HCl/dioxane (1:1) at 80° for 4 h. After the dioxane was removed, H_2O (5 ml) was added and the soln. was extracted with AcOEt (5 ml \times 3). The aq. fractions were evaporated and the residues were prepared as thiazolidine derivatives for GC analysis according to the methods described in the literature [8].

Ilexperoside C (= (3 β)-3-(β -D-Glucopyranosyloxy)-19,23-dihydroxyurs-12-en-28-oic Acid; **1**). Colorless gum. $[\alpha]_{\text{D}}^{25} = +9.6$ ($c = 2.5$, MeOH). IR (KBr): 3420, 2934, 1691, 1453, 1076, 1037. ^1H - and ^{13}C -NMR: Tables 1–3. ESI-MS (pos.): 673 ($[M + \text{Na}]^+$). HR-ESI-MS (pos.): 673.3944 ($[M + \text{Na}]^+$, $\text{C}_{36}\text{H}_{58}\text{NaO}_{10}^+$; calc. 673.3928).

Ilexperoside D (= (3 β)-19,23,28-Trihydroxy-28-oxours-12-en-3-yl β -D-Glucopyranosiduronic Acid; **2**). Colorless gum. $[\alpha]_{\text{D}}^{25} = +5.15$ ($c = 0.7$, MeOH). IR (KBr): 3415, 2931, 1683, 1202, 1046. ^1H - and ^{13}C -NMR: Tables 1–3. ESI-MS (pos.): 687 ($[M + \text{Na}]^+$). HR-ESI-MS (pos.): 687.3716 ($[M + \text{Na}]^+$, $\text{C}_{36}\text{H}_{56}\text{NaO}_{11}^+$; calc. 687.3720).

Ilexperoside E (= 1-*O*-[(2 α ,3 β)-3-[(6-Butyl- β -D-glucopyranuronosyl)oxy]-2,23-dihydroxy-28-oxours-12-en-28-yl]- β -D-glucopyranose; **3**). White, amorphous powder. $[\alpha]_{\text{D}}^{25} = -3.33$ ($c = 0.9$, MeOH). IR (KBr): 3421, 2925, 1739, 1587, 1066. ^1H - and ^{13}C -NMR: Tables 1–3. ESI-MS (pos.): 905 ($[M + \text{Na}]^+$). HR-ESI-MS (pos.): 905.4835 ($[M + \text{Na}]^+$, $\text{C}_{46}\text{H}_{74}\text{NaO}_{16}^+$; calc. 905.4875).

Ilexperoside F (= 1-*O*-[(3 β)-3-[[6-Butyl-4-*O*-(β -D-glucopyranosyl)- β -D-glucopyranuronosyl]oxy]-28-oxoolean-12-en-28-yl]- β -D-glucopyranose; **4**). White, amorphous powder. $[\alpha]_{\text{D}}^{25} = +5.71$ ($c = 0.7$, MeOH). IR (KBr): 3421, 2929, 1742, 1632, 1463, 1074. ^1H - and ^{13}C -NMR: Tables 1–3. ESI-MS (pos.): 1035 ($[M + \text{Na}]^+$). HR-ESI-MS (pos.): 1035.5496 ($[M + \text{Na}]^+$, $\text{C}_{52}\text{H}_{84}\text{NaO}_{19}^+$; calc. 1035.5505).

Ilexpernoside G (= (3 β)-3-[[2-O-(6-Deoxy- α -L-mannopyranosyl)- β -D-glucopyranosyl]oxy]-19,23-dihydroxyurs-12-en-28-oic Acid; **5**). Colorless gum. $[\alpha]_{\text{D}}^{25} = -9.0$ ($c = 3.0$, MeOH). IR (KBr): 3422, 2931, 1691, 1628, 1385, 1048. ^1H - and ^{13}C -NMR: *Tables 1, 2, and 4*. ESI-MS (pos.): 797 ($[M + \text{H}]^+$). HR-ESI-MS (pos.): 797.4675 ($[M + \text{H}]^+$, $\text{C}_{42}\text{H}_{60}\text{O}_{14}^+$; calc. 797.4687).

Ilexpernoside H (= 1-O-[(3 β)-3-[[3-O-(β -D-Glucopyranosyl)- α -L-arabinopyranosyl]oxy]-23-hydroxy-28-oxours-12-en-28-yl]- β -D-glucopyranose; **6**). Colorless gum. $[\alpha]_{\text{D}}^{25} = +13.3$ ($c = 1.5$, MeOH). IR (KBr): 3421, 2925, 1727, 1676, 1456, 1075, 1030. ^1H - and ^{13}C -NMR: *Tables 1, 2, and 4*. ESI-MS (pos.): 929 ($[M + \text{H}]^+$). HR-ESI-MS (pos.): 929.5082 ($[M + \text{H}]^+$, $\text{C}_{47}\text{H}_{77}\text{O}_{18}^+$; calc. 929.5100).

Ilexpernoside I (= (3 β)-3-[[2-O-(β -D-Glucopyranosyl)- β -D-glucopyranosyl]oxy]-19,23-dihydroxyurs-12-en-28-oic Acid; **7**). White, amorphous powder. $[\alpha]_{\text{D}}^{25} = +0.029$ ($c = 2.5$, MeOH). IR (KBr): 3451, 2925, 1696, 1457, 1077, 1030. ^1H - and ^{13}C -NMR: *Tables 1, 2, and 4*. ESI-MS (pos.): 813 ($[M + \text{H}]^+$). HR-ESI-MS (pos.): 813.4630 ($[M + \text{H}]^+$, $\text{C}_{42}\text{H}_{60}\text{O}_{15}^+$; calc. 813.4636).

Ilexpernoside J (= 1-O-[(3 β)-3-[[2-O-(β -D-Glucopyranosyl)- α -D-glucopyranosyl]oxy]-23-hydroxy-28-oxours-12-en-28-yl]- β -D-glucopyranose; **8**). White, amorphous powder. $[\alpha]_{\text{D}}^{25} = +13.01$ ($c = 4.6$, MeOH). IR (KBr): 3428, 2928, 1669, 1632, 1074. ^1H - and ^{13}C -NMR: *Tables 1, 2, and 4*. ESI-MS (pos.): 975 ($[M + \text{H}]^+$). HR-ESI-MS (pos.): 975.5157 ($[M + \text{H}]^+$, $\text{C}_{48}\text{H}_{79}\text{O}_{20}^+$; calc. 975.5165).

REFERENCES

- [1] Delectis Florae Reipublicae Popularis Sinicae Agendae Academiae Sinicae Edita, 'Flora Reipublicae Popularis Sinicae', Science Press, Beijing, 1999, Vol. 45, Fascicule 2, p. 94.
- [2] Jiangsu New Medical College, 'Dictionary of Chinese Materia Medica', Shanghai Science and Technology Press, Shanghai, 1986, p. 844.
- [3] K. Nishimura, T. Fukuda, T. Miyase, H. Noguchi, X.-M. Chen, *J. Nat. Prod.* **1999**, 62, 1061.
- [4] K. Nishimura, T. Miyase, H. Noguchi, *J. Nat. Prod.* **1999**, 62, 1128.
- [5] K. Nishimura, T. Miyase, H. Noguchi, X.-M. Chen, *Nat. Med.* **2000**, 54, 297.
- [6] W.-J. Qin, X. Wu, J.-J. Zhao, F. Yoshiyasu, Y. Tosihide, N. Kazuyuki, *Phytochemistry* **1986**, 25, 913.
- [7] Z.-J. Wu, M.-A. Ouyang, C.-Z. Wang, Z.-K. Zhang, J.-G. Shen, *J. Agric. Food Chem.* **2007**, 55, 1712.
- [8] L. Tang, Y. Jiang, H.-T. Chang, M.-B. Zhao, P.-F. Tu, J.-R. Cui, R.-Q. Wang, *J. Nat. Prod.* **2005**, 68, 1169.
- [9] S.-X. Zhou, J.-S. Yang, F.-C. Liu, P.-F. Tu, *Helv. Chim. Acta.* **2007**, 90, 121.
- [10] G.-B. Xie, L.-D. Lei, P.-F. Tu, *Magn. Reson. Chem.* **2007**, 45, 997.
- [11] S. Sahpaz, M. P. Gupta, K. Hostettmann, *Phytochemistry* **2000**, 54, 77.
- [12] S. Shimizu, N. Ishihara, K. Umehara, T. Miyase, A. Ueno, *Chem. Pharm. Bull.* **1988**, 36, 2466.
- [13] M. Hu, K. Ogawa, Y. Sashida, P.-G. Xiao, *Phytochemistry* **1995**, 39, 179.
- [14] V. D. Huan, S. Yamamura, K. Ohtani, R. Kasai, K. Yamasaki, N. T. Nham, H. M. Chau, *Phytochemistry* **1998**, 47, 451.
- [15] G. M. Woldemichael, M. Wink, *J. Agric. Food Chem.* **2001**, 49, 2327.
- [16] M. Ukiya, T. Akihisa, K. Yasukawa, H. Tokuda, T. Suzuki, Y. Kimura, *J. Nat. Prod.* **2006**, 69, 1692.
- [17] W.-C. Ye, B.-X. Ou, N.-N. Ji, S.-X. Zhao, T. Ye, M. A. McKervey, P. Stevenson, *Phytochemistry* **1995**, 39, 937.
- [18] H. Kawai, M. Kuroyanagi, K. Umehara, A. Ueno, M. Satake, *Chem. Pharm. Bull.* **1988**, 36, 4769.

Received March 11, 2008